LabCorp/$LH
1D1W1MYTD1Y5YMAX
Capital at risk
About LabCorp
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
- Ticker
- $LH
- Sector
- Health
- Primary listing
- NYSE
- Employees
- -
- Headquarters
- Burlington, United States
- Website
- www.labcorp.com
LabCorp Metrics
BasicAdvanced
$25B
25.42
$12.08
0.84
$2.16
0.94%
Price and volume
Market cap
$25B
Beta
0.84
52-week high
$341.80
52-week low
$244.52
Average daily volume
660K
Dividend rate
$2.16
Financial strength
Current ratio
1.796
Quick ratio
1.246
Long term debt to equity
76.968
Total debt to equity
78.464
Dividend payout ratio (TTM)
23.86%
Interest coverage (TTM)
7.12%
Profitability
EBITDA (TTM)
2,319.8
Gross margin (TTM)
28.88%
Net profit margin (TTM)
6.99%
Operating margin (TTM)
11.28%
Effective tax rate (TTM)
18.66%
Management effectiveness
Return on assets (TTM)
5.53%
Return on equity (TTM)
11.73%
Valuation
Price to earnings (TTM)
25.418
Price to revenue (TTM)
1.764
Price to book
2.89
Price to tangible book (TTM)
-11.82
Price to free cash flow (TTM)
21.909
Free cash flow yield (TTM)
4.56%
Free cash flow per share (TTM)
14.011
Dividend yield (TTM)
0.70%
Forward dividend yield
0.94%
Growth
Revenue change (TTM)
6.41%
Earnings per share change (TTM)
33.20%
3-year revenue growth (CAGR)
6.53%
10-year revenue growth (CAGR)
4.55%
3-year earnings per share growth (CAGR)
9.15%
10-year earnings per share growth (CAGR)
7.04%
What the Analysts think about LabCorp
Analyst ratings (Buy, Hold, Sell) for LabCorp stock.
Analyst projections of the future price of LabCorp stock.
Bulls say / Bears say
Labcorp’s operating momentum is strong: second-quarter 2026 revenue rose 5.8%, adjusted EPS increased 14.9%, and management raised full-year adjusted EPS guidance to $18.10–$18.55. (Reuters)
Specialty diagnostics and biopharma services provide growth avenues beyond routine testing. Recent launches and expansions in oncology, companion diagnostics, genetic testing, and consumer health are aligned with management’s focus on higher-growth testing categories. (Labcorp)
Capital returns could support per-share growth: Labcorp added $1.0 billion to its share-repurchase authorization, leaving $1.4 billion available, while guiding to $1.24–$1.36 billion of 2026 free cash flow. (Labcorp)
Reimbursement remains a structural risk: Labcorp’s latest 10-Q warns that unfavorable changes in government or commercial payer policies, utilization management, and rising patient responsibility could pressure collections, profitability, and cash flow. (SEC)
Labcorp’s acquisition-led strategy increases execution and balance-sheet risk. The company reported $5.86 billion of debt at June 30, 2026, invested $427.9 million in acquisitions year-to-date, and cautioned that failed integration could reduce synergies while increasing indebtedness. (Labcorp)
The company remains exposed to labor, customer-retention, and test-volume risks despite recent growth. Labcorp specifically cites labor unrest, employee retention, customer concentration or loss, lower testing volumes, and unfavorable service mix as potential threats to results. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
LabCorp Financial Performance
Revenues and expenses
LabCorp Earnings Performance
Company profitability
Upcoming events
No upcoming events
LabCorp News
AllArticlesVideos
Funds containing LabCorp
AllEURGBPUSD
Fund name | Fund size | $LH weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.55% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.43% |
iShares S&P 500 Equal Weight€O4J0 | €4.3B | 0.23% |
iShares S&P 500 Equal Weight£EWSP | £3.7B | 0.22% |
iShares MSCI USA SRI$SUAS | $3.4B | 0.17% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.